Haemostasiologic effects of various glucose-lowering medications in type 2 diabetes mellitus
| Autor: | G. G. Petrik, S. A. Pavlishchuk |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2010 |
| Předmět: | |
| Zdroj: | Кардиоваскулярная терапия и профилактика, Vol 9, Iss 2, Pp 48-53 (2010) |
| Druh dokumentu: | article |
| ISSN: | 1728-8800 2619-0125 |
| Popis: | Aim. To evaluate the effects of insulin and other glucose-lowering medications on platelet function and coagulation haemostasis in patients with Type 2 diabetes mellitus (DM-2). Material and methods. The study included 147 patients with DM-2, aged 49—60 years (mean age 54 years), not receiving any glucose-lowering therapy, or regularly taking various glucose-lowering medications (glibenclamide, gliclazide, metformin, insulin, and glibenclamide + metformin combination). Results. Platelet function activation and increased pro-coagulation activity are typical for DM-2 patients, including individuals at early DM stages, without angiopathy, and not receiving pharmaceutical treatment. Various groups of glucose-lowering medications have different effects on hemostasis parameters. Specifically, insulin, glibenclamide, metformin and glibenclamide + metformin combination do not have any anti-aggregant activity. At the same time, insulin and glibenclamide activate the internal coagulation pathway. Anti-platelet activity of glibenclamide is similar to that of acetylsalicylic acid. Conclusion. Different haemostasiologic effects of glucose-lowering medications should be considered while choosing individual treatment strategy in DM-2 patients. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|